Cargando…

High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study

OBJECTIVE: Pharmacological treatment of non-alcoholic fatty liver disease (NAFLD) is still evolving. Probiotics could be a promising treatment option, but their effectiveness needs to be established. The present study aimed to evaluate the efficacy of a high potency multistrain probiotic in adult pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duseja, Ajay, Acharya, Subrat K, Mehta, Manu, Chhabra, Shruti, Rana, Satyavati, Das, Ashim, Dattagupta, Siddhartha, Dhiman, Radha K, Chawla, Yogesh K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688701/ https://www.ncbi.nlm.nih.gov/pubmed/31423319 http://dx.doi.org/10.1136/bmjgast-2019-000315

Ejemplares similares

Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial
por: Sakpal, Mallikarjun, et al.
Publicado: (2017)

Association between metabolic syndrome and liver histology among NAFLD patients without diabetes
por: Kanwar, Pushpjeet, et al.
Publicado: (2016)

Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker
por: Baselli, Guido Alessandro, et al.
Publicado: (2020)

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
por: Montagner, Alexandra, et al.
Publicado: (2016)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Tomah, Shaheen, et al.
Publicado: (2021)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients With Review of Literature
por: Nath, Preetam, et al.
Publicado: (2022)

Genetic polymorphism in CD14 gene, a co-receptor of TLR4 associated with non-alcoholic fatty liver disease
por: Kapil, Shweta, et al.
Publicado: (2016)

Mechanisms of liver disease in patients infected with HIV
por: Kaspar, Matthew B, et al.
Publicado: (2017)

NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression
por: Latif, Muhammad Umair, et al.
Publicado: (2022)

Drug idiosyncrasy due to pirfenidone presenting as acute liver failure: Case report and mini‐review of the literature
por: Verma, Nipun, et al.
Publicado: (2017)

Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population
por: Kolhe, Kailash Marotrao, et al.
Publicado: (2019)

Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)
por: Chawla, Kashmira S, et al.
Publicado: (2016)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

Dysregulated activation of fetal liver programme in acute liver failure
por: Hyun, Jeongeun, et al.
Publicado: (2019)

Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis
por: Jarvis, Helen, et al.
Publicado: (2022)

Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort
por: Olubamwo, Olubunmi O, et al.
Publicado: (2019)

STAT4-associated natural killer cell tolerance following liver transplantation
por: Jamil, K M, et al.
Publicado: (2017)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells
por: Dai, Zhen, et al.
Publicado: (2020)

Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites
por: Zhang, Xiang, et al.
Publicado: (2021)

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia
por: Maev, Igor V, et al.
Publicado: (2020)

Hyperbilirubinaemia in HIV–HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?
por: Kaspar, Matthew B, et al.
Publicado: (2016)

Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD
por: Al-Karaghouli, Mustafa, et al.
Publicado: (2022)

Loss of hepatic Mboat7 leads to liver fibrosis
por: Thangapandi, Veera Raghavan, et al.
Publicado: (2021)

The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018
por: Liu, Jie, et al.
Publicado: (2022)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
por: Mózes, Ferenc Emil, et al.
Publicado: (2022)

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
por: Hallsworth, Kate, et al.
Publicado: (2011)

Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia
por: Chihota, Belinda Varaidzo, et al.
Publicado: (2022)

Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial
por: Haigh, Laura, et al.
Publicado: (2021)

The human liver microenvironment shapes the homing and function of CD4(+) T-cell populations
por: Wiggins, Benjamin G, et al.
Publicado: (2022)

Monocyte human leukocyte antigen – Antigen D related, neutrophil oxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure
por: Satsangi, Sandeep, et al.
Publicado: (2018)

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
por: Scarzello, Anthony J, et al.
Publicado: (2016)

Changing trends of hospitalisation of liver cirrhosis in Beijing, China
por: Bao, Xiao-Yuan, et al.
Publicado: (2015)

Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Xu, Xiao, et al.
Publicado: (2016)

Does COVID-19 infection significantly affect liver transplantation? Results of liver transplantation in the COVID-19 era at a single, high-volume centre
por: Moradi, Alimohammad, et al.
Publicado: (2023)

Neutrophil dysfunction predicts 90‐day survival in patients with acute on chronic liver failure: A longitudinal case–control study
por: Makkar, Kunaal, et al.
Publicado: (2020)

Relevance of vitamin D on NAFLD and liver fibrosis detected by vibration controlled transient elastography in US adults: a cross-sectional analysis of NHANES 2017–2018
por: Ji, Yuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q31h7iounjjfl881j6egpirnkb